EUVIMEDOpdag EUVIMED
Crossref

Liver Fibrosis and the Risk of Coronary Artery Disease, Stent Thrombosis, Restenosis and Adverse Clinical Outcomes

Na Tian, Tie Xiao iD, Tianyi Xia, Hai-Yang Yuan, Michael D Shapiro, Gregory Y H Lip, Cheng-Han Fanren, Li-You Lian, Chen-Xiao Huang, Yi-Xuan Wei, Giovanni Targher iD, Christopher D Byrne and 4 more

Alimentary Pharmacology & Therapeutics · 2026

DOI: 10.1111/apt.70306 ↗

At a glance

Journal article in Alimentary Pharmacology & Therapeutics, 2026. Written by Na Tian and 15 co-authors. Institution: Department of Hepatology, MAFLD Research Center, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. Major MEDLINE topics: Liver Cirrhosis, Coronary Artery Disease, Coronary Restenosis, Stents. Cited 8 times so far (Crossref); 41 references. Funded by: NIHR Southampton Biomedical Research Centre, National Natural Science Foundation of China, School of Medicine, University of Verona.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background and Aims Liver fibrosis may be associated with coronary artery disease (CAD) and adverse cardiovascular outcomes, but data remain limited. This study aimed to explore the relationship between liver fibrosis and the incidence of CAD, stent thrombosis (ST), in‐stent restenosis (ISR) and long‐term clinical outcomes.

Methods

Two cohorts were analysed: the UK Biobank (UKB) cohort examined liver fibrosis and CAD incidence and clinical outcomes in the general population, while the Wenzhou cohort assessed its relationship with ST and ISR and long‐term outcomes in post‐PCI patients. CAD incidence was defined as coronary stenosis ≥ 50% or clinical events, such as myocardial ischaemia, myocardial infarction and acute coronary syndrome. ST was confirmed via angiography, and ISR was defined as ≥ 50% stenosis within the stent. Major adverse cardiovascular events (MACE) included all‐cause mortality, myocardial infarction, heart failure and stroke. Liver fibrosis was assessed using FIB‐4, categorised as ≤ 1.3, 1.3–2.67 and > 2.67.

Results

394,625 participants were included. In the UKB cohort ( n = 380,638), 7102 (1.9%) had FIB‐4 > 2.67. Over 14.4 years, FIB‐4 > 2.67 was associated with higher CAD incidence (aHR = 1.41, p < 0.001) and MACE (aHR = 1.69, p < 0.001). In the Wenzhou cohort ( n = 13,987), 3173 (22.7%) had FIB‐4 > 2.67. Over 3.0 years, FIB‐4 > 2.67 was associated with increased risks of ST and ISR (aHR = 1.34, p = 0.001) and MACE (aHR = 1.97, p < 0.001).

Conclusions

Liver fibrosis is common among patients with CAD and is associated with CAD incidence, stent thrombosis, restenosis and long‐term cardiovascular risk.

Subjects

MeSH terms (MEDLINE)

Liver CirrhosisCoronary Artery DiseaseCoronary RestenosisStentsThrombosisHumansMaleFemaleMiddle AgedAgedRisk FactorsIncidenceCohort StudiesUnited KingdomTreatment OutcomePercutaneous Coronary Intervention

Author keywords

coronary artery diseasefibrosis‐4 scoremajor adverse cardiovascular eventspercutaneous coronary interventionrestenosisstent thrombosis

Authors and institutions

  • Department of Hepatology, MAFLD Research Center, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
  • Nurturing Center of Jiangsu Province for State Laboratory of AI Imaging & Interventional Radiology (Southeast University), Department of Radiology, Zhongda Hospital, Medical School of Southeast University, Nanjing, Chin…
  • Center for Prevention of Cardiovascular Disease, Section on Cardiovascular Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
  • Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, UK.
  • Department of Clinical Medicine, Danish Center for Health Services Research, Aalborg University, Aalborg, Denmark.
  • Department of Cardiovascular Medicine, the Heart Center, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.

ORCID profiles: Tie Xiao, Giovanni Targher, Shenghong Ju, Ming-Hua Zheng

Funding

  • NIHR Southampton Biomedical Research Centre
  • National Natural Science Foundation of China
  • School of Medicine, University of Verona
  • National Key Research and Development Program of China
  • National Institute for Health Research Southampton Biomedical Research Centre

Cite

APA

Tian, N., Xiao, T., Xia, T., Yuan, H. Y., Shapiro, M. D., Lip, G. Y. H., Fanren, C. H., Lian, L. Y., Huang, C. X., Wei, Y. X., Targher, G., Byrne, C. D., Hong, C. L., Ju, S., Zheng, M. H., & WMU MAFLD Clinical Research Working Group (2026). Liver Fibrosis and the Risk of Coronary Artery Disease, Stent Thrombosis, Restenosis and Adverse Clinical Outcomes. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70306

Vancouver

Tian N, Xiao T, Xia T, Yuan HY, Shapiro MD, Lip GYH, et al. Liver Fibrosis and the Risk of Coronary Artery Disease, Stent Thrombosis, Restenosis and Adverse Clinical Outcomes. Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.70306

BibTeX
@article{Tian2026,
  author = {Tian, Na and Xiao, Tie and Xia, Tianyi and Yuan, Hai-Yang and Shapiro, Michael D and Lip, Gregory Y H and Fanren, Cheng-Han and Lian, Li-You and Huang, Chen-Xiao and Wei, Yi-Xuan and Targher, Giovanni and Byrne, Christopher D and Hong, Cheng-Lv and Ju, Shenghong and Zheng, Ming-Hua and WMU MAFLD Clinical Research Working Group, WMU MAFLD Clinical Research Working Group},
  title = {Liver Fibrosis and the Risk of Coronary Artery Disease, Stent Thrombosis, Restenosis and Adverse Clinical Outcomes},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2026},
  doi = {10.1111/apt.70306}
}
Start for free →